Editorials

All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies
K.P. Liao, V. Bykerk .......................... 1223

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis
J.E. Homik .................................. 1225

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri ..................... 1228

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau ........................................ 1231

Review

Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists
E.C. Keystone, K.A. Papp, W. Wobeser .......................... 1234

Articles

Lymphotixin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?

Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort S. Varache, D. Cornec, J. Morvan, et al ............ 1250


A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis A. Svärd, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh ................................. 1265

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry J.A. Markenson, A. Gibofsky, W.R. Palmer, et al ............ 1273

Time to Treatment for New Patients with RA in a Major Metropolitan City S. Jamal, S.M.H. Aibhai, E.M. Badley, C. Bombardier ........................................ 1282

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China X. Feng, Y. Zou, W. Pan, et al .......................... 1289

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression A. Mak, Y. Liu, R.C-M Ho ........................................ 1296

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos .................... 1304

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms A.D. Askarane, I. Castrejón, T. Pincus ........................................ 1309

Late-age Onset SSc R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers .... 1317

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group ........................................ 1326


Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy, A Randomized Controlled Trial S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Negro, R. Ramonda, L. Punzi ................................. 1335


Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych ................................. 1349


Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene S. Borghini, M. Fiore, M. Di Duca, et al .......................... 1378

Free online via JRheum Full Release option
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
P.A. Merkel, S.Z. Aydin, M. Boers, et al 1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update
P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group 1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG
L.C. Coates, A. Mumtaz, P.S. Helliwell, et al 1496

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde 1502


Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group 1514

Correspondence
Where in the World is Oral Triamcinolone? L. Roger 1519
Reply R. Aitken 1519

Lupus Related Longitudinal Myelitis
D.M. Wingerchuk, B.G. Weisman 1520
Reply P. Zotos 1521

Who Discovered the ESR? A. Grzybowski, J.J. Sak 1521
Reply E.L. Matteson, C.S. Crowson 1523

Letters
Serum Levels of HMG1 in Postmenopausal Patients with RA: Associations with Prolinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics

Acute Presentation of Tophaceous Myelopathy
E. Levin, K. Hurth, R. Joshi, R. Brasington 1525

AS Refractory to TNF Blockade Responds to Tocilizumab
J-D. Cohen, R. Ferreira, C. Jorgensen 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis
M. Uh, I.A. McCormick, J.T. Kelsall 1528

Primary Aldosteronism Simulating Polymyositis
Y-C. Tang, S-K. Wang, W-L. Yuan 1529

Corrections
Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial
J.A. Singh, M.L. Mahowald, S. Noorbalaocchi 1534

Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis
S. Shafii, M.J. Fritzler, M.D. Mayes, et al 1534

Meetings in Rheumatology